Document:

Joint Manufacturing Agreement

 Exhibit 10.49 

CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS 

DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED 

WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE 

CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH 

THE SECURITIES AND EXCHANGE COMMISSION. 

JOINT MANUFACTURING AGREEMENT 

between 
 Amyris Brasil S.A. 

 CNPJ/MF
n.o 09.379.224/0001-20 

Rua James Clerk Maxwell, 315 
 City of
Campinas, State of São Paulo 
 Brazil 

herein represented by its undersigned legal representatives, 

hereinafter called “AMYRIS” 

and 
 Biomin do Brasil
Nutrição Animal Ltda. 

CNPJ/MF 
n.o 07.738.662/0001-02 

Estrada Professor Messias Jose Baptista, 2700City of Piracicaba, State of São Paulo 

Brazil 
 herein represented by its
undersigned legal representatives, 
 hereinafter called “BDB” and, together with AMYRIS, the
“Parties” 
 WITHNESSETH: 

WHEREAS, AMYRIS is in need of having available certain products described in more detail hereinafter, 

WHEREAS, BDB is engaged in the manufacturing of similar products and it is willing to manufacture the products required by AMYRIS, 

WHEREAS, AMYRIS intends to procure and acquire the equipment necessary for the production of said products by BDB and to install them at BDB’s
plant located in the city of Piracicaba, implementing, henceforth, the Expansion of BDB’s Plant, as to allow BDB to perform the joint manufacturing hereby agreed upon (“Expansion”); 

 WHEREAS, further to the acquisition and installation of two fermenters to be acquired by AMYRIS,
pursuant to the Expansion, BDB intends to acquire a third fermenter for its own use and at its own expense, and both of the Parties intend to procure and negotiate the acquisition of the three (3) ferments jointly, as to have more bargain power
and share the benefits of such a joint negotiation; and 
 WHEREAS, AMYRIS intends to entrust BDB with the manufacturing of such products,
providing BDB with the necessary information and equipment, and paying BDB a consideration. 
 NOW, THEREFORE, in consideration of the
mutual promises and covenants contained in this Joint Manufacturing Agreement (this “Agreement”), the parties hereto have agreed and do hereby agree as follows: 

TABLE OF CONTENTS 
  

	 1
	 Scope of Agreement 

	 2
	 Licenses and Approvals, GMM Certification 

	 3
	 Purchasing and Free Lease of the Equipment, Expansion (calculation, time-schedule) and Insurance 

	 4
	 Logistics, Supply of Raw Materials 

	 5
	 Information, Decontamination 

	 6
	 Production Forecasts, Manufacturing of Stock 

	 7
	 Pricing, Payment Term 

	 8
	 By-products (spent yeast) 

	 9
	 Title of the Product and Developments 

	 10
	 Representations and Warranties, Additional Obligations 

	 11
	 Breach of Agreement, Indemnity 

	 12
	 Confidentiality 

	 13
	 Force Majeure 

	 14
	 Term, Termination 

	 15
	 Purchase Option 

	 16
	 Infringement of Intellectual Property Rights, Indemnification 

	 17
	 Applicable Law, Dispute Resolution 

	 18
	 Miscellaneous 

  

 
  

	 1
	 Scope of Agreement 

1.1        BDB agrees to manufacture, in its current facility in Piracicaba (“Plant”), a certain
product specifically required by AMYRIS (“Joint Manufacturing”), as detailed and specified within Annex A (“Product”), according to the terms and conditions set forth in this Agreement. 

1.1.1    The Parties agree that the scope of this Agreement comprises all activities necessary for performance of the Joint
Manufacturing, from the entrance of the Raw Materials (as defined in section 4.1 below) into the Plant, to the delivery of the Product, including, but not being limited to the storage of Raw Materials, the manufacturing of the Product, product
testing, product storage, and by-product handling at the Plant, all according to the Standard Operating Procedures (“SOPs”), 

 
to be provided by AMYRIS, in order to allow BDB to manufacture the Products. The Parties agree that the SOPs shall be analyzed and approved by the Technical Board, but that AMYRIS will,
nonetheless, remain solely liable for their content. The general guidelines of the SOPs are attached to this Agreement as Annex D and the Parties agree that the actual SOPs shall also be an integral part of this Agreement. 

1.2        The Parties are aware that the Joint Manufacturing requires the acquisition of certain
equipment, to be used exclusively for the manufacturing of the Product (the “Equipment”). Therefore, the Parties agree that AMYRIS will procure and contract the engineering works and the necessary Equipment for the Expansion, as well as
lease the acquired Equipment to BDB, free of charge, retaining the title to such new Equipment. A detailed description of the necessary Equipment and estimation of its cost of acquisition is attached hereto as Annex B. 

1.3        In order to give support to the performance of this Agreement, the parties will establish the
following bodies, which will perform the activities described below: 
  

	 	 (i)
	 Joint Project Team (“Project Team”), constituted of members from both Parties and led by an AMYRIS project leader, which will be responsible for
Expansion of the Plant and for the engineering, installation and start-up of the Equipment in the Plant, pursuant to the Expansion (“EPC Activities”); 

	 	 (ii)
	 A Management Committee (“Management Committee”), constituted of 4 members, having one leader designated by each of the Parties. This Committee shall
be responsible for monitoring the operation of Plant, including budget decisions, without limiting BDB’s responsibility for manufacturing the Products in accordance with the SOPs. Decisions to be made by the Management Committee will require
unanimous approval; 

	 	 (iii)
	 A Technical Advisory Board (“Technical Board”), constituted of 5 members – 2 each from AMYRIS and BDB, and one external member not belonging to
any of the Parties’ regular personnel. The Technical Board shall be responsible for setting the best practices to be observed in the entire facility, including the Joint Manufacturing and the ongoing BDB operation, especially those related to
aseptic operations and prevention of cross contamination. The Technical Board shall also be required to analyze and sign-off on designs and operational SOPs. 

1.3.1    The parties agree that the Technical Board shall be formed no later than five (5) days after the
execution of this Agreement, in order to provide appropriate guidance in connection herewith, from its commencement. 

1.3.2    The Parties agree that the Project Team and the Management Committee shall be constituted no later
than ten (10) days before the first piece of Equipment is purchased by AMYRIS. For the purposes of such deadline, AMYRIS will notify BDB, in writing, about the purchase of the first piece of Equipment. 

1.4        In the event the actual anticipated costs for the Equipment exceeds the maximums set forth in
Annex B, the Parties will negotiate in good faith fair adjustments of costs and fees contemplated under the Agreement. Unless otherwise agreed by the Management Committee, AMYRIS shall pay for any such cost overrun of the Equipment.

 2          Licenses and Approvals, GMM
certification 
 2.1       BDB will be responsible for obtaining and maintaining, for the duration
of this Agreement, all approvals and licenses of its Plant, necessary for the Joint Manufacturing. 
 2.1.1    AMYRIS
commits to reimburse BDB for all reasonable expenses incurred by BDB to obtain production permits, if any, to the extent specifically and exclusively related to and required for the Joint Manufacturing of Products under this Agreement. 

2.2       AMYRIS will be exclusively responsible for obtaining and maintaining, for the duration of this
Agreement, all approvals and licenses necessary for the Product. BDB will support AMYRIS in the process of obtaining said Products’ approvals and licenses, by means of providing all documents and information, in BDB’s power and or related
to BDB’s Plant, required by relevant authorities for that purpose. 
 2.3       Without limiting
Section 2.1, BDB shall commit its best efforts to obtain, as promptly as possible, and within the production schedules agreed to by the Parties under this Agreement, any additional approvals and licenses that may be necessary for the Joint
Manufacturing in its Plant. 
 2.4       AMYRIS and BDB will work together to extend the AMYRIS CQB
certification to the Plant. AMYRIS will bear any costs to obtain such extension. 
 2.5       The
Parties will endeavor all efforts to obtain a Special Regime from Tax Authorities for the proper execution of this Agreement, if necessary. 

3          Purchasing and Free Lease of the Equipment, Expansion (calculation, time-schedule)
and Insurance 
 3.1       AMYRIS will procure, contract and manage the EPC Activities. AMYRIS
shall be responsible for payment of the entire Project Capex according to the calculation and time-schedule and any additional terms and conditions within Annex B. BDB will provide, at no charge, all support reasonably requested by AMYRIS in
connection with EPC Activities, including, without limitation, giving information on the Plant, making available internal technical teams to follow the installation procedures, making sure all requirements set forth in the applicable licenses are
being complied with during installation and start-up. Unless otherwise agreed by the Management Committee, AMYRIS shall be responsible for any capital expenditure incurred by BDB for modifications to the existing Plant that may be needed to support
the installation and operation of the Equipment. The additional costs paid by AMYRIS under this Section shall be accrued to the account of capital expenditures incurred in the Expansion (“Project Capex”) if and as determined by the
Management Committee. 
 3.2       The Parties shall investigate the most cost-effective approach for
obtaining the necessary scope of insurance on the Equipment acquired for the Joint Manufacturing. During the term of this Agreement any such insurance related expenses shall be borne by AMYRIS, provided that: (i) if AMYRIS determines to insure
the Equipment directly, it will be responsible for payment directly to the 

 
insurers; (ii) if the Parties agree that the Equipment should be insured under BDB’s insurance policies, AMYRIS will reimburse BDB for that portion of any insurance premiums directly
related to coverage for such Equipment within the Plant. 
 3.3.     AMYRIS and BDB agree to, by all means
possible, endeavor their best efforts to install the Equipment and the fermenter to be acquired by BDB at the same time, in order to minimize potential service disruptions associated with the installation works. 

4          Logistics, Supply of Raw Materials 

4.1       AMYRIS shall be responsible for procurement and delivery to BDB of raw materials described in Annex
C (“Raw Materials”). BDB will be responsible for providing the utilities and ancillary infrastructure as necessary to perform the Joint Manufacturing in the Plant, such as, without limiting, water & waste facilities,
electricity, manpower, phone services, access to internet and other services reasonably expected for the operation of an industrial plant. The consumption of these supplies furnished by BDB will be measured through specific meters to be installed by
BDB, to avoid confusion with the consumption of the other production lines in BDB Plant. 

4.2       AMYRIS will supply Raw Materials to the Plant in such quantities and at such times as required to
enable BDB to manufacture the Products according to AMYRIS’s forecast. 
 4.3.      AMYRIS shall be
responsible for transportation costs and insurance of the Raw Materials thereof in connection with inbound and outbound logistics of Raw Materials and Products to and from the Plant. 

4.4.      AMYRIS shall be responsible for product liability insurance on Raw Materials. BDB shall be responsible for
proper handling and storage of Raw Materials at the Plant, which should be done in accordance to the SOPs, including insuring against loss or damage to the Raw Materials. 

4.5       BDB will notify AMYRIS of any non-compliance of supplied Raw Materials with the specifications
contained in the SOPs and any shortage in quantity of any shipment of supplied Raw Materials promptly upon learning of such non-compliance or shortage and prior to the processing of the Raw Materials concerned. BDB shall not process Raw Materials
that do not meet AMYRIS’s specifications without AMYRIS’s prior written permission. 

4.6       AMYRIS will use all reasonable commercial efforts to supply raw materials for BDB’s own use not
related to this Agreement under the same conditions applied to raw materials to be jointly manufactured under this Agreement. 

5          Information, Decontamination 

5.1       AMYRIS will make available to BDB the SOPs necessary to allow BDB to manufacture the Products. BDB
shall employ all such SOPs and its own knowledge and experience to perform its obligations under this Agreement. AMYRIS will assign two members of its personnel to supervise activities at the Plant, such number being subject to increase in the event
that AMYRIS, in agreement with BDB, deems it 

 
appropriate. BDB will provide suitable offices and telephone, network and Internet access to such personnel, as well as access to all facilities, supplies, books and records relating to the Plant
and the Joint Manufacturing of Products under this Agreement. 
 5.2       The Project Team members of
each of the Parties shall meet on a regular basis to discuss technical and related questions including possible improvements to the manufacturing process. Further to the exchange of information by the project leaders of each BDB and AMYRIS teams,
AMYRIS shall receive a monthly report, in electronic format, containing relevant information regarding the production of the Products. 

5.3       The Parties agree that the production supervision by AMYRIS shall not exclude BDB’s sole
liability for the manufacturing of Products according to the SOPs, except when a certain damage or delay has occurred as a direct result of an action carried out by AMYRIS personnel or exclusively due to a defect of the SOPs or except for any event
provided for in Clause 13. 
 5.4       Due to substantial differences between the Products and other
products manufactured by BDB, both Parties will use all reasonable commercial efforts to ensure that no cross–contamination can take place between BDB’s other operations and the Raw Materials, Products, and by-products (including spent
yeast) used or produced in the Plant. Without limiting the foregoing, BDB will establish new working shift schedules and adhere to certain SOPs concerning decontamination. Such schedules will be based on, and subject to, the forecasts mentioned
within Section 6.1 below. AMYRIS, by its turn, will endeavor its reasonable best efforts as to avoid contamination, starting with the engineering process, providing appropriate guidance, training and supervision to BDB with respect to the Joint
Manufacturing. Both of the Parties will endeavor their best efforts to obtain and follow the instructions given by the Technical Board. 

5.5       AMYRIS hereby confirms that no antibiotic-resistance-markers will be used in connection with the Joint
Manufacturing of the Products or will be part of AMYRIS’ GMO yeast strains. 
 5.6.      AMYRIS hereby
agrees to provide a test method to identify colonies of AMYRIS yeast. 

6          Production Forecasts, Manufacturing of Stock 

6.1       Commencing one month in advance of the expected date the Equipment is certified to begin commercial
production at the Plant, and thereafter prior to the end of each calendar month, AMYRIS shall provide BDB with production forecasts concerning its requirements of Products for the following three (3) calendar months. AMYRIS will ensure that BDB
has adequate quantity of Raw Materials to meet the forecasted requirements. In the event AMYRIS adjusts its Product requirements by greater than 15% from the forecast for any monthly / three-month period, the Parties will discuss appropriate
adjustments, if any, in the manufacturing fee for that period resulting from non-cancellable commitments, expedited Raw Material and/or overtime costs incurred to accommodate such change. 

6.2       BDB agrees to receive supplied Raw Materials and to manufacture the Products in accordance to SOPs as
stipulated within Annex A. The manufacturing 

 
activities will be carried out by BDB with its own employees, and no labor, subordination, or any relationship shall be deemed to be created between such employees and AMYRIS. All Products will
be subject to acceptance testing as stipulated in Annex A, under which AMYRIS shall verify whether the manufactured Products comply with the volume and quality requirements agreed on. If any of such requirements is not complied with, the
Technical Board shall assess and determine what caused such non conformation of the Product. 

6.3       BDB shall be responsible for storing the finished Products, as specified in the SOPs. 

7          Pricing, Payment Term 

7.1       AMYRIS shall pay to BDB a manufacturing fee (“Fee”) as set forth within Annex E,
which shall comprise the total operating costs plus a margin as set forth therein. 
 7.1.1    This
Fee shall cover all operational expenses related to the production of the Products, including: 
  

	 	 •
	 	 Labor necessary for the Joint Manufacturing; 

	 	 •
	 	 Provided utilities and ancillary infrastructure facilities; 

	 	 •
	 	 Use of any piece of machinery/equipment used by BDB and not part of the Equipment to be supplied by AMYRIS (e.g. centrifuges, storage area, lifts etc);

	 	 •
	 	 Management overhead; 

	 	 •
	 	 Maintenance of the Equipment dedicated to the Joint Manufacturing; 

	 	 •
	 	 Cost of direct and indirect consumables, such as antifoam, soda, acid, filters, used in the Joint Manufacturing. 

7.1.2    This Fee shall be based on a monthly review of the actual operating costs. Annex E contains a
list of unit costs and estimation of operating expenses. If, at any month, BDB incurs in any additional cost unit for the manufacturing of the Products not described in such annex, the Parties shall negotiate to achieve the most equitable cost
allocation between them. 
 7.2       BDB shall issue by fifth
(5th) day of each calendar month an invoice exclusively for charging
purposes (detailing the basis for the amounts according to the abovementioned calculation) to AMYRIS for the previous calendar month. Unless otherwise agreed in writing, payment shall be made by bank transfer within thirty (30) days after
receipt of an undisputed invoice. AMYRIS will notify BDB within ten (10) days after receipt of an invoice if AMYRIS disputes the amount or calculation of the Fee, describing the basis for the dispute. BDB will provide AMYRIS with additional
support for the calculation of the Fee, and make available any books and records requested by AMYRIS related to the elements and calculation of the Fee. AMYRIS will pay the invoiced Fee or an adjusted Fee based on such review within fifteen
(15) days following receipt of the additional materials from BDB. 
 7.3       The Fee shall be
calculated excluding any tax, whether value added tax or any other tax. Each Party shall pay any tax imposed on each component of the fee according to the applicable laws. However, any tax that must be settled through payment deductions, according
to applicable laws and regulations, as well as any 

 
social contributions eventually imposed to AMYRIS, in connection with the manufacturing activities, may be deducted by AMYRIS from the fee amount to be paid to BDB. 

7.3.1    The fiscal documents must also be issued according to the applicable laws or any Special Regime potentially granted by
Tax Authorities for the execution of this Agreement. 
 7.4       Calculation of invoice amount shall
be made on an open book basis, meaning that AMYRIS shall have access to BDB’s account records in connection with the Joint Manufacturing of the Products. The accounting prepared by BDB will be audited by an independent auditor chosen by the
Parties at the end of each fiscal year. AMYRIS and BDB will share the costs of this auditing. 

7.5       The currency for invoicing and payment shall be Brazilian reais. 

8.         By-products (spent yeast) 

8.1       BDB shall duly quantify and physically return to AMYRIS all of the by-products (i.e., spent yeast)
from the Joint Manufacturing, along with the Product. 
 8.2       BDB may be interested in spent yeast
from the industrial process of the Product. Therefore, AMYRIS agrees to negotiate in good faith with BDB, at any time in which BDB notifies AMYRIS about its actual interest in the spent yeast. Upon receipt of the relevant notification, Amyris and
BDB will also negotiate in good faith the use of spent yeast generated at both the Joint Manufacturing operation as well as the new AMYRIS facility in Pradopolis. 

9          Title of the Product and Developments 

9.1       BDB agrees that the title to the Products, the SOPs, and any other information or materials regarding
the recipe and manufacturing process for the Products, as well as any inventions, improvements, modifications or derivatives to the foregoing developed by or for either Party in the course of this Agreement (“Developments”), shall at all
times be vested in AMYRIS. BDB hereby assigns and agrees to assign to AMYRIS any intellectual, industrial or other proprietary rights BDB may obtain in or to such information, materials or Developments. During the term of this Agreement and
following any expiration or termination, BDB will execute such documents as reasonably requested by AMYRIS in order for AMYRIS to perfect, maintain and protect its rights in such items. To the extent a Development cannot be assigned in accordance
with this Section, BDB hereby grants AMYRIS an unrestricted, nonexclusive, irrevocable, perpetual, transferable, royalty-free license (with the right to sublicense) to such Development, including the right to make, use, sell, offer to sell, copy,
distribute, modify and create derivative works of any item, product or process comprising or incorporating the Development. 

9.2       AMYRIS hereby agrees to grant a nonexclusive, irrevocable, perpetual, royalty-free, license to BDB for
use of technical knowledge generated out of the performance of the joint manufacturing operations that is unrelated to the AMYRIS process. 

 9.3       BDB shall, as quickly as possible, inform AMYRIS about
any allegations made by third parties with regards to AMYRIS’s property or property rights. If necessary, BDB shall cooperate with AMYRIS, providing all needed information for the defense of AMYRIS’s proprietary rights against third
parties. 
 10        Representations and Warranties, Additional Obligations 

 

	 10.1     Each
	 of the Parties represents and warrants that: 

  

	 	 (i)
	 it has been duly incorporated, is validly existing and in good standing under the laws of Brazil; 

 

	 	 (ii)
	 it has full power and authority, and has taken all required corporate and other action necessary to execute and deliver this Agreement and to fulfill its
obligations hereunder; 

  

	 	 (iii)
	 this Agreement constitutes a legal, valid and binding obligation, enforceable against it in accordance with its terms; 

 

	 	 (iv)
	 no order, consent, approval or authorization of, or registration, declaration or filing with any governmental authority is required to be obtained in
connection with the execution, delivery and performance of this Agreement or the consummation of the transactions contemplated hereby, except as already set forth in this Agreement. 

10.2     Additionally, BDB warrants that the Products will be manufactured in accordance with best industry practices and
the SOPs, provided that all materials, services or workmanship supplied by BDB to AMYRIS under this Agreement will conform to such SOPs. Without limiting the foregoing, BDB warrants that, at all times, it shall comply with all applicable laws, rules
and regulations in the performance of its obligations under this Agreement. 
 10.3     In the case the Products
do not comply with the Product Specifications due to non-compliance with the SOPs or due to disruption of BDB’S Plant operations not related with a force majeure event, BDB shall be held responsible for such Product flaw. In the case the
Products do not comply with the Product Specifications due to any fail in the SOPs or to a defect in the yeast supplied, AMYRIS should be held responsible for such flaw. As provided for in Section 6.2, the Technical Board will be responsible
for evaluating and determining which Party was responsible for the non-conformation of the final Product with the Product Specifications, or, as the case may be, to what extent each of the Parties was responsible for that. 

10.4     In the case the Technical Board decides that BDB was responsible for the non conformation of the Products under
Section 10.3 above, BDB will lose its entire Fee over the relevant amounts of Product manufactured. In case responsibility for flaws is attributed to AMYRIS, AMYRIS will acquire the Product and pay the Fee agreed in this Agreement. In the case
the Technical Board holds both AMYRIS and BDB responsible for non-conformation of the Products, the Parties will accordingly apply a discount over the Fee due for the manufactured Product. 

10.4.1 Regardless of which Party is held responsible for the non-conformation of the Products with the Product Specifications, and
to what extent, AMYRIS will, at all times, be responsible for disposal of spent yeast, which shall be 

 
duly quantified and physically returned to AMYRIS, by BDB, along with the Product, as per Section 8.1 above. 

10.5     In case of non-conformation of Products, both Parties will fully comply with the corrective action proposed by
the Technical Board to rectify the cause of the non-conformation, in order to get production of Products back on track. 

10.6     Amyris represents and warrants that the Products, including all components thereof, will be safe when
(i) manufactured by BDB in accordance with the SOPs and any other applicable guidelines and standards set forth in this Agreement or reasonably furnished by AMYRIS to BDB in writing and handled in accordance with the applicable safety
instructions contained in such documents. 
 10.7     Neither AMYRIS nor BDB shall entice or hire any employee of
the other Party during the term of this Agreement and for a term of one year following its expiration. 

11        Breach of Agreement, Indemnity 

11.1     Each Party (“Indemnifier”) shall defend, indemnify and hold harmless the other Party and its directors,
officers, representatives, agents, affiliates, successors and assignees (“Indemnified Party”) from and against all loss, damage, liability, cost and expense (including reasonable attorneys’ fees) resulting from (i) the breach of
any of the Indemnifier’s obligations under this Agreement, or (ii) the non-compliance with any representations and warranties set forth herein. 

11.1.1 Immediately after having knowledge of any act or fact giving rise to an indemnification under this Section 11.1, the
Indemnified Party shall send to the Indemnifier a notice to that effect with a description of such act or fact and a copy of any relevant document. If, despite their best efforts, the Parties are not able reach a mutually acceptable settlement
deemed reasonable by both Parties within fifteen (15) days from the receipt of such notice, the applicable Indemnified Party may then initiate an arbitration procedure in accordance with Section 17 hereof. 

11.1.2 All payments to the applicable Indemnified Party shall be in immediately available funds and any indemnification payment
must be grossed up to cover any and all taxes payable by the applicable indemnified party on account of such payment. 

11.2     Additionally, the Indemnifier shall defend, indemnify and hold harmless the Indemnified Party from and against
all loss, damage, liability, cost and expense (including reasonable attorneys’ fees) resulting from any claim presented by a third party relating to any personal injury or property damage caused by the negligence or willful misconduct of the
Indemnifier, provided, in each case, that the Indemnified Party (a) notifies the Indemnifier in writing of the claim promptly after receiving service of process or any written communication relating to the claim; (b) grants the Indemnifier
control of the defense and settlement of the claim; and (c) provides Indemnifier with all assistance, information and representation powers reasonably required for the defense and settlement of the claim, at Indemnifier’s expense.

 11.2.1 Notwithstanding Section 11.2, the Parties agree that, in case of any claim brought by a third party against
AMYRIS arising from injury or damage 

 
resulting from the operating activities carried out by BDB within the Unit and the Plant, including relating to the breach of environmental legal requirements and obligations, BDB shall be deemed
the Indemnifier under this Section 11.2, and shall be strictly liable for losses arising from such claim before AMYRIS, without prejudice to BDB’s right to present the appropriate defense before the relevant third party. Nonetheless, in
case BDB is not able to obtain the exclusion of AMYRIS as defendant in the relevant judicial or administrative procedure within thirty (30) days from AMYRIS’s knowledge of the claim, AMYRIS will be entitled to follow and intervene in the
defense procedure. 
 11.3     In the event either Party fails to pay any undisputed amount owed on any due date
for any payment as agreed in this Agreement, it shall pay a flat fine equal to two percent (2%) over the due and unpaid amount, plus interest accrued from the due date to the date on which the entitled Party has received such payment at a rate
equal to one percent (1%) per month. 
 12       Confidentiality 

12.1    Confidential information shall be any and all specifications, samples, manuals, reports, documentation, test results,
data, calculations, know-how or other information (“Confidential Information”) supplied by one Party (“Disclosing Party”) to the other (“Receiving Party”) in tangible form, as well as the terms and conditions of this
Agreement. 
 Provided that the following information shall not be deemed Confidential Information: 

 

	 	 a)
	 information intended by the Disclosing Party to be used by the Receiving Party as promotional material; 

 

	 	 b)
	 information that was in the public domain, other than by breach of this Agreement or a subsequent agreement between the Parties; 

 

	 	 c)
	 information that was already known by the Receiving Party prior to its disclosure by the Disclosing Party; 

 

	 	 d)
	 information that was already published at the time of disclosure by the Disclosing Party, or has since become so published through no fault of the Receiving
Party; 

  

	 	 e)
	 information that has been lawfully received by the Receiving Party from a third party without breach of any obligation of confidentiality owed to the
Disclosing Party; or 

  

	 	 f)
	 information with regards to which the Receiving Party is bound by applicable laws or regulations to disclose, provided that the Receiving Party notifies the
Disclosing Party of such disclosure with a written notice delivered within 24 (twenty-four) hours after the requirement was made by the relevant authority. 

 The burden of proving the applicability of any of these exceptions to “Confidential
Information” resides with the Receiving Party. 
 12.2    During the term of this Agreement, as well as after its
expiration, neither AMYRIS nor BDB will use Confidential Information obtained from the other party, except as reasonably necessary to perform its obligations or exercise its rights under this Agreement. 

12.3    Each Party shall, therefore, during the term of this Agreement, as well as after its expiration, keep confidential all
Confidential Information supplied by the other Party, and neither Party’s employees or any other person acting on their behalf will copy Confidential Information or disclose it to any third party without the other Party’s written consent.
Neither Party will disseminate any Confidential Information among its employees or persons acting on their behalf, except to the extent strictly necessary for the purposes of this Agreement, and each Party will use its best efforts to ensure that no
person copies, discloses or uses Confidential Information except as hereby permitted; in this connection, each Party shall use at least the same degree of care in safeguarding Confidential Information as a prudent tradesman and as it would in
safeguarding its own information of a similar nature. 
 12.4    The Receiving Party shall, therefore, not make or
have made any copies or recordings of the Confidential Information, except insofar as necessary for said purposes, provided that such sets or copies or recordings should be numbered consecutively. 

12.5    All Confidential Information disclosed shall at the latest be returned to the Disclosing Party promptly following
termination or expiration of this Agreement. 
 12.6    In the event the Disclosing Party gives the Receiving Party
written authorization to disclose Confidential Information to a third party, the Receiving Party shall obtain a written agreement of such third party that limits use and disclosure of such information in a manner reflecting the wording of this
Section 12. 
 12.7    Notwithstanding the above, BDB hereby agrees that AMYRIS may disclose the content of this
Agreement and of the relationship between the Parties to investors or underwriters coordinating the raising of capital for AMYRIS or its controlling entities, as long as the information provided to such third parties is limited to the strictly
necessary for the relevant capital raising procedure. 
 13       Force Majeure 

13.1    The Parties shall be exempt from liability in respect of any failure to perform the obligations under this Agreement
due to circumstances unforeseeable and beyond their reasonable control such as war, acts of terrorism, fire, epidemic, or acts of God, as well as any kind of production downtime due to reason’s that were not under BDB’s control. The Party
wishing to claim relief under this Section 13 shall, without delay, accordingly notify the other Party in writing. The Party affected shall promptly use all reasonable efforts to settle such contingencies so that the performance of its
obligations under this Agreement can be resumed as soon as possible. 

 13.2    Should either Party claim the continuation of force majeure beyond sixty
(60) days, the other party may terminate this Agreement by delivering a ten (10) days prior written notice to the other Party. 

14       Term, Termination 

14.1    This Agreement shall become effective on its date of execution (the “Effective Date”) and shall continue in
full force and effect until five (5) years following the Effective Date (the “Expiration Date”). Following such term, BDB and AMYRIS may, upon mutual consent, which may be given or withheld by each party in its sole and absolute
discretion, extend the Agreement for one (1) more year. In this case, the Parties shall execute a formal document stating their intent to extend the Agreement for one more year, at least six (6) months in advance from the Expiration Date.

 14.2    Either Party may terminate this Agreement at any time prior to the Expiration Date according to
Section 14.1 by sending a written notice to the other Party: 
  

	 	 (a)
	 if the other Party materially breaches this Agreement, and such breach is not cured within thirty (30) days of written notice to the breaching Party.
Such written notice has to explicitly include the statement that the Agreement can be terminated in the event the breach is not cured within said thirty (30) days; 

 

	 	 (b)
	 if the other Party is subject to proceedings for bankruptcy, judicial recovery, liquidation or dissolution, or ceases to carry on its business;

  

	 	 (c)
	 if after exploitation of all technical and operational prospects the issue of cross contamination still cannot be satisfactorily solved;

  

	 	 (d)
	 in case of change in the direct shareholding control of any of the Parties without the authorization of the other Party. 

14.2.1 In case of early termination of the Agreement due to fault of BDB, AMYRIS shall have the option to remove the Equipment from BDB’s
Plant. 
 14.2.2 Without prejudice to the provision of item 14.2(d) above, in case BDB or its controlling entities intend to implement a
corporate restructuring (merger, spin-off, acquisition, amalgamation) that will result in the transfer of the ownership of the Plant to a third party (i.e., a party that is not a BDB affiliate), the Parties agree that AMYRIS shall have a right of
first refusal to acquire the Plant. For this purpose, BDB shall send a written communication to notify AMYRIS of its intention to transfer the ownership of the Plant and the terms and conditions under which such transfer is to be carried out,
including a copy of the third party offer that will result in the transfer of the ownership of the Plant. AMYRIS will then have a period of ten (10) days to send a written response to BDB, with regards to its intention to exercise, or not, its
right of first refusal, under the same terms and conditions of transfer informed by BDB. Should AMYRIS decide not to exercise its right of first refusal, it will, nonetheless, have the right to terminate this Agreement and immediately and prior to
the conclusion of the transfer of the ownership of the Plant to a third party remove the Equipment from the Plant. 

14.3    Additionally, this Agreement will be terminated upon exercise, by BDB, of the purchase option relating to the
Equipment, as set forth in Section 15.1 below and 

 
also in the relevant free lease agreement executed between the Parties, for lease of the Equipment, by Amyris to BDB, free of charge (“Free Lease Agreement”). 

14.4    From and after the termination or expiration of this Agreement, neither of the Parties hereto shall have any further
rights, privileges or obligations hereunder, except that such expiration or termination shall not relieve the Parties of any liability accrued prior to the effective date of such expiration or termination, and such expiration or termination shall
not affect the continued operation or enforcement of any provisions of this Agreement, which by its express terms is to survive termination or expiration. 

14.5    Should this Agreement be terminated, BDB shall return to AMYRIS all the Raw Materials and Products stored in its Plant.

 15       Purchase Option 

15.1    As more specifically set forth in the Free Lease Agreement, after a period of two (2) years as of the Effective
Date, BDB shall have the option to purchase the Equipment for a price equal to the total Project Capex less taxes less depreciation accrued in accordance with applicable fiscal law. The Project Capex account shall be submitted to BDB promptly after
completion of installation of the Equipment and is subject to referendum by the Management Committee. 
 15.2    If
BDB does not exercise the option referred to in Section 15.1 after a period of two (2) years as of the Effective Date, in the third anniversary of this Agreement, BDB shall have a final option to purchase the Equipment for the price
defined in Section 15.1. 
 15.3    The Parties hereby agree that the Purchase Option provided for in this
Section 15 and in the Free Lease Agreement shall comprehend the whole of the Equipment and, hence, the total Project Capex. [*]. 

16       Infringement of Intellectual Property Rights, Indemnification 

16.1    AMYRIS warrants that, to the best of its knowledge, the manufacturing of the Products, or any item thereof, does not
violate any third party’s intellectual or industrial property rights. 
 16.2    Without prejudice to
Section 9.2 above, AMYRIS hereby agrees to defend, indemnify and hold harmless BDB, its officers, agents, affiliates, successors and assigns, from and against any liability, cost and expense (including reasonable attorneys’ fees) arising
out of or related to any claim being made or action brought against BDB alleging that BDB’s manufacture of Products in accordance with this Agreement infringes the intellectual or industrial property rights of a third party, provided that BDB
(a) promptly notifies the AMYRIS in writing of the claim; (b) grants AMYRIS sole control of the defense and settlement of the claim; and (c) provides AMYRIS with all assistance, information and authority reasonably required for the
defense and settlement of the claim, at AMYRIS’s expense. Notwithstanding 
  

 
 *Certain information on
this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 the above, AMYRIS shall not have any obligation under this Section 16 to the extent such
infringement is based on BDB’s use of equipment, materials, processes or procedures not supplied or required by AMYRIS under this Agreement. THE FOREGOING SHALL BE BDB’S SOLE RESPONSIBILITY, AND AMYRIS SHALL NOT HAVE ANY OTHER LIABILITY,
WITH RESPECT TO ANY ACTUAL OR ALLEGED INFRINGEMENT OF THE INTELLECTUAL OR INDUSTRIAL PROPERTY RIGHTS OF ANY THIRD PARTY RESULTING FROM THE MANUFACTURING OF PRODUCTS OR FROM THE MANUFACTURING, USE OR DISTRIBUTION OF ANY BY-PRODUCTS OF SUCH PRODUCTS.

 17       Applicable Law, Dispute Resolution 

 

	 17.1    This
	 Agreement shall be governed by the laws of Brazil. 

17.2    The Parties will use best efforts to resolve any difference of opinion and dispute in friendly negotiations.

 17.3    If friendly negotiations pursuant to Section 17.2 do not result in an agreement within ninety
(90) days from the first communication sent by one Party to the other on the relevant matter, all disputes arising out of or in connection with this Agreement shall be exclusively and finally settled by arbitration, under the Rules of
Arbitration of the Câmara de Comércio Brasil Canadá, by arbitrator(s) appointed in accordance with these Rules. The decision of the arbitrator(s) shall be final and binding upon the Parties with no further appeal, recourse
or review. Until such decision, the Parties agree to keep the arbitration procedure on a confidential basis, except to the extent necessary for any interim or conservatory measures permitted under the Rules of Arbitration. 

17.4    The place of Arbitration shall be the city of São Paulo, State of São Paulo, Brazil. 

17.5    All documents and correspondence in relation to those disputes shall be drafted in Portuguese and English and the
arbitration proceedings shall be conducted in Portuguese and English. 
 17.6    The arbitrators to be appointed shall
be fluent in written and spoken English and Portuguese. 
 17.7    Notwithstanding the above, either Party may request
judicial measures: (i) in order to obtain preliminary and urgent measures (medidas cautelares) or temporary injunction or other conservatory relief in any court having jurisdiction to protect or preserve its confidential information,
proprietary rights, or personal prior to the formation of the arbitral tribunal, and such judicial recourse shall not be interpreted as a waiver of the arbitration as set forth in this section; and (ii) to enforce any arbitral decision,
including the final award. For that purpose, the Parties elect the courts of the city of São Paulo, State of São Paulo, Brazil, being waived any other no matter how privileged it may be. The Parties recognize that any provisional or
urgent matter granted by judicial courts shall be, necessarily, reviewed by the arbitral tribunal, which shall decide on its ratification, revision or cancellation. 

18       Miscellaneous 
  

	 18.1    Compliance
	 with laws and rules: 

 When performing its obligations under this Agreement, both Parties shall strictly observe all
applicable laws and regulations. AMYRIS shall not in any case be responsible for the compliance with any labor, environmental and other laws applicable to the operation of the Plant. 

18.2    Assignment:  

No Party is entitled to assign rights and obligations under this Agreement either wholly or in part to a third party without the prior written
consent of the other Party, provided that either party may assign this Agreement without consent to one of its affiliates. 

18.3    Severability:  

If any portion of this Agreement shall be declared void or unenforceable by any court or administrative body of competent jurisdiction, such portion
shall be deemed severable from the remainder of this Agreement, which shall continue in all respects valid and enforceable. The Parties shall mutually agree to cooperate in any revision of this Agreement which may be necessary to meet the
requirements of law. 
 18.4    Entire Agreement:  

This Agreement including its Annexes constitutes the entire Agreement between the Parties with respect to the subject matter as of the date hereof
and supersedes all prior discussions, understandings and Agreements with respect to the subject matter. 

18.5    Contract Language and Notices: 

The language for any communication in connection with this Agreement or any amendment shall be English and Portuguese. Any notice hereunder shall be
in writing and shall be delivered to the other party at its last known business address by the most expeditious means, including but not limited to first class mail, airmail, fax and e-mail. Such notices shall be effective upon receipt. 

18.6    No Waiver: 

Except as specifically provided in a written waiver signed by a duly authorized officer of the party seeking enforcement, failure to enforce or the
waiver of any term of this Agreement shall not constitute the waiver of such term at any time or in any circumstances and shall not give rise to any restriction on or condition to the prompt, full and strict enforcement of the terms of this
Agreement. 
  

	 18.7    Headings:
	 

 Section headings are for
convenience only and shall not form part of this Agreement or in any way affect the interpretation thereof. 
  

	 18.8    Survivorship:
	  

 All provisions of
Section 8.2, Section 10.3, Section 11, Section 12, Section 14, Section 16, Section 17 and this Section 18 shall survive termination of this Agreement for any cause and shall not be affected thereby.

 IN WITNESS hereof, this Agreement is executed in 2 (two) counterparts of the same form and content, in
the City of São Paulo, State of São Paulo, Brazil, on June 24, 2010. 
 Intentionally left blank — signature pages
following 

 Signature Page 1/3 of the Joint Manufacturing Agreement, entered into as of June 24, 2010, between
Amyris Brasil S.A. and Biomin do Brasil Nutrição Animal Ltda. 
 AMYRIS BRASIL S.A. 

 

					
		 		 	
			
	 /s/ Roel Win Collier
	 		 	 /s/ Felipe Moreira Caram

	 Name: Roel Win Collier
	 		 	 Name: Felipe Moreira Caram

	 Title: General Manager
	 		 	 Title: Financial Officer

 Signature Page 2/3 of the Joint Manufacturing Agreement, entered into as of June 24, 2010, between
Amyris Brasil S.A. and Biomin do Brasil Nutrição Animal Ltda. 
 BIOMIN DO BRASIL NUTRIÇÃO ANIMAL LTDA.

  

					
		 		 	
			
	 /s/ Herbert Danner
	 		 	 /s/ Edilberto Ferrerira

	 Name: Herbert Danner
	 		 	 Name: Edilberto Ferreira

	 Title: General Manager
	 		 	 Title: Financial Officer

 Signature Page 3/3 of the Joint Manufacturing Agreement, entered into as of June 24, 2010, between
Amyris Brasil S.A. and Biomin do Brasil Nutrição Animal Ltda. 
  

	
	 Witnesses:

	
	  
	 Name:
 ID (RG)
No.:
 Tax Reg. (CPF/MF) No.:

	
	
	  
	 Name:
 ID (RG)
No.:
 Tax Reg. (CPF/MF) No.:

 LIST OF ANNEXES 

 

			
	 Annex A
	  	 Products to be manufactured / Product Specifications

		
	 Annex B
	  	 Estimated cost of Equipment / calculation, time-schedule

		
	 Annex C
	  	 List of Raw Materials provided by AMYRIS

		
	 Annex D
	  	 SOP General Guidelines

		
	 Annex E
	  	 Estimated manufacturing Fee / Description of Operating Costs

		
	 Annex F
	  	 Trans-beta-farnesene Material Data Safety Sheet

 ANNEX A 

Products to be manufactured / Product Specifications 
  

	 •
	 Trans-beta-farnesene 

  

	 	 o
	 Product specification: See Material Data Safety Sheet (MSDS) Annex E 

 

	 	 o
	 Acceptance Tests: to be determined based on mutually agreed upon SOP’s. 

 

	 •
	 Other products based on mutual agreement between the two Parties 

 ANNEX B 

Estimated cost of Equipment / calculation, Specification of the Equipment 

and Time-schedule 
  

									
	Equipment	  	Equipment/service	  	Description	  	Quantity	  	Gross cost
					
		  		  	[*]	  		  	

  
  

Specification of the Equipment 
  

									
	 	 	 	  	 Equipment
	  	Gross cost	  	 
					
		 		  	[*]	  		  	

  

									
		 		  	Project schedule:	  		  	
					
		 		  	[*]	  		  	

  
  

 
  

*Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 ANNEX C 

List of Raw Materials provided by AMYRIS 
  

	 	 •
	 	 Sugar (syrup, juice, VHP, or other appropriate media) 

 ANNEX D 

SOP General Guidelines 
 To be
completed at a later time by the parties 

 ANNEX E 

Estimated manufacturing Fee / Description of Operating Costs 

Overall estimates of the monthly operating cost as well as mechanisms to estimate elements of the actual operating cost are provided in this
section. 
 The various elements comprising the overall operating cost and their estimates are provided in the table below: 

 

									
	  	  	Unit cost	  	Fixed cost	  	 Estimated

monthly

usage
	  	 Estimated

monthly cost

					
		  		  	[*]	  		  	

 The following unit cost will be valid for each cost element. 

 

									
	 	 	 	 	 Unit cost
	  	 Basis of unit cost
	  	 
					
		 		 	[*]	  		  	
	 	 	 	 	 	  	 	  	 
	
	 The mechanism to estimate the monthly usage of each element of operating cost is provided below. These mechanisms will be used to evaluate actual operating
cost on a monthly basis.

					
	 	 	 	 	 Estimated monthly

usage
	  	 Basis of monthly usage estimate
	  	 
		 		 	[*]	  		  	

  
  

 
  
  

 
  

 
 * Certain information
on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ANNEX F 

Trans-beta-farnesene Material Data Safety Sheet 

(sheet begins on the next page) 

 MATERIAL SAFETY DATA SHEET 

 
  

SECTION 1. COMPANY AND MATERIAL IDENTIFICATION 
  

 
  

			
	 Product Name:
	  	 Trans-ß-FARNESENE

		
	 Company:
	  	
		  	 AMYRIS BIOTECHNOLOGIES INC

		
	 Street Address:
	  	 5885 HOLLIS ST, SUITE 100

		  	 EMERYVILLE, CA 94608, U.S.A.

	 CITY, STATE, ZIP, COUNTRY:
	  	
		
	 For Technical Assistance During

Normal Working Hours (9-5 P.S.T.):
	  	 1 (510) 450-0761

	 In Case of Emergency, call:
	  	 1 (800) 424-9300 (CHEMTREC – North America)

1 (703) 527-3887 (CHEMTREC – International)

This material safety data sheet (MSDS) has been prepared in compliance with the US Federal OSHA Hazard Communication Standard (29 CFR 1910.1200).
This material is considered hazardous under that standard. 
  
  

SECTION 2. PRODUCT COMPOSITION 
  

 
  

			
	 SUBSTANCE NAME:
	  	 ß-FARNESENE

	 CAS #:
	  	 18794-84-8

	 MOLECULAR

FORMULA:
	  	
C15H
24

	 SYNONYMS:
	  	 1,6,10-Dodecatriene, 7,11-dimethyl-3-methylene, (6E) (TSCA,

PICCS, ASIA-PAC)

1,6,10-Dodecatriene, 7,11-dimethyl-3-methylene, (E) (DSL, AICS)

(E)-7,11-Dimethyl-3-methylenedodeca-1,6,10-triene (EINECS)

(E)-7,11-Dimethyl-3-methylene-1,6,10-dodecatriene (ECL)

		
	 CHEMICAL FAMILY:
	  	 Terpene hydrocarbons

  

 
 SECTION 3. HEALTH HAZARDS 

 
  

WARNING STATEMENT/EMERGENCY OVERVIEW 

CAUTION! Chemical intended to be handled by trained personnel for R&D purposes only. To the best of our knowledge the toxicity of this
chemical and potential target organ toxicity is not fully known. Avoid skin contact, eye contact, inhalation, and ingestion. For additional information on toxicity, please refer to Section 11. 

EMERGENCY OVERVIEW 
  

			
	 OSHA Hazards Labeling
	  	 May be eye and skin irritant

		
	 HMIS Hazard Classification
	  	 Health: 1

Flammability: 1

			
		
		  	 Physical Hazards: 0

		
	 NFPA Rating
	  	 Health: 1
 Fire:
1
 Reactivity: 0

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: None known. 

OCCUPATIONAL EXPOSURE LIMIT: None currently established for the chemical by OSHA, NIOSH, ACGIH or Amyris. 

 
  

SECTION 4. FIRST AID MEASURES 
  

 
 EYE CONTACT 

Immediately flush eyes thoroughly with water for at least 15 minutes. Notify medical personnel and supervisor. 

SKIN CONTACT 
 Immediately
wash thoroughly with soap and water for 15 minutes. Notify medical personnel and supervisor. In the case of skin irritation or allergic reaction, consult a physician. 

INHALATION 
 Immediately move
to fresh air. If not breathing give artificial respiration or, if breathing is difficult, give oxygen and notify medical personnel and supervisor. 

INGESTION 
 If person is
conscious, administer a moderate amount (8-12 oz. or 250 mL) of water, but do not induce vomiting. Notify medical personnel and supervisor. 

NOTE TO PHYSICIAN 
 As the
toxicity of this chemical is not fully known, treatment should be based on the symptoms of the patient and the judgment of the physician in response to the condition and reaction of the patient. 

 
  

SECTION 5. FIRE PROTECTION 
  

 
 FLAMMABILITY/EXPLOSIVITY

 No unusual hazards. 

EXTINGUISHING MEDIA 
 For
small incipient fires use media such as alcohol-resistant foam, dry chemical or carbon dioxide. For large fires apply water from as far as possible. Use very large quantities of water applied as a mist or spray. Cool affected containers with large
quantities of water. 
 SPECIAL FIRE FIGHTING PROCEDURES 

Wear NIOSH/MSHA-approved, positive pressure, self-contained breathing apparatus and protective clothing to prevent skin or eye contact. Class IIIB
combustible material. May emit toxic fumes under fire conditions. 
  

			
	 Flash Point (TCC):
	  	 110 °C (230 °F)

	 Autoignition Temperature:
	  	 Not determined

	 Explosion Limits, Lower (%):
	  	 Not determined

			
	 Upper (%):
	  	 Not determined

  

 
 SECTION 6. SPILL AND RELEASE MEASURES

  
  

PERSONAL PRECAUTIONS 
 Use
personal protective equipment. Use suitable respirator when performing operations involving potential exposure to vapors, mist or gas of the product. Ensure adequate ventilation. 

ENVIRONMENTAL PRECAUTIONS 

Prevent product from entering drains. 

METHODS FOR CLEANING UP 

Soak up with inert absorbent material. Keep in suitable, closed containers for disposal as hazardous waste. 

 
  

SECTION 7. HANDLING AND STORAGE 
  

 
 HANDLING PRECAUTIONS 

Use personal protective equipment. Avoid breathing vapor. Do not eat, drink or smoke while handling this product. Avoid prolonged or repeated
exposure. Provide sufficient air exchange and/or exhaust in workrooms. Take precautionary measures against static discharges. Use normal preventative fire protection measures. 

STORAGE PRECAUTIONS 
 Keep
container tightly closed. Keep in a cool and well ventilated area. To maintain product quality, do not store in heat or direct sunlight. 
  

 
 SECTION 8. EXPOSURE CONTROL/PERSONAL
PROTECTION 
  
  

HYGIENE MEASURES 
 Avoid
contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. 
 RESPIRATORY PROTECTION

 Respiratory protection is not required. When desired use multifunctional NIOSH approved gas/vapor cartridges. 

SKIN PROTECTION 
 Protective
gloves are recommended to minimize potential for skin contact when handling. Wear long sleeves and other protective overgarment, such as an apron or sleeve covers. Base the choice of protection on the job activity and potential for skin contact.

 EYE PROTECTION 

Wear safety glasses with side shields, chemical splash goggles, or full face shield, if necessary. Base the choice of protection on the job activity
and potential for contact with eyes or face. 
 OTHER 

 Work in chemical hoods and/or well ventilated areas. Provide safety showers and eye washes.
Decontaminate all protective equipment after use. 
  
  

SECTION 9. PHYSICAL/CHEMICAL PROPERTIES 
  

 
  

			
	 Appearance:
	  	 Colorless to pale yellow liquid

		
	 Odor:
	  	 Woody

		
	 Melting Point:
	  	 < 0°C (<32°F)

		
	 Boiling Point:
	  	 206°C (403°F) at 1,103 hPa (760 mm Hg)

		
		  	 124°C (255°F) at 12 mm Hg

		
	 Molecular Weight:
	  	 204.36

		
	 Density:
	  	 0.807 g/mL

		
	 Refractive Index:
	  	 1.48400 - 1.49400 @ 20.00 °C.

		
	 Solubility:
	  	 Insoluble (water)

		
		  	 Soluble (alcohols)

		
	 Vapor Pressure:
	  	 Not determined

		
	 pH:
	  	 Not determined

		
	 LogP
	  	 7.17

		
	 Viscosity, dynamic:
	  	 Not determined

		
	 Specific Gravity:
	  	 0.82300 - 0.83400 @ 25.00 °C.

		
	 Vapor Density:
	  	 >1 (Air = 1)

		
	 Evaporation Rate:
	  	 Not determined

  

 
 SECTION 10. STABILITY AND REACTIVITY 

  
  

STABILITY 
 Stable under
recommended storage conditions 
 INCOMPATIBILITY 

Avoid strong oxidizing agents 

HAZARDOUS DECOMPOSITION PRODUCTS 

If a material is in a fire, may release small quantities of carbon monoxide, carbon dioxide and 

water 
  

 
 SECTION 11. TOXICOLOGICAL INFORMATION

  
  

Also see Section 3. Health Hazards 

 ACUTE TOXICITY 

Acute oral toxicity of trans-ß-FARNESENE
LD50 >5000 mg/kg 

Acute dermal toxicity of trans-ß-FARNESENE
LD50 > 5000 mg/kg 

May be harmful if swallowed or inhaled. 

IRRITATION AND CORROSION 

Trans-ß-FARNESENE is a dermal irritant and may be an eye irritant. 

SENSITISATION 
 No evidence
of sensitization for trans-ß-FARNESENE. 
 CHRONIC EXPOSURE 

No component of this product present at levels greater than or equal to 0.1% is identified as a probable, potential or confirmed human carcinogen by
IARC, ACGIH, NTP or OSHA. Trans-ß-FARNESENE has tested negative for mutagenicity by the Ames test. 
  

 
 SECTION 12. ENVIRONMENTAL INFORMATION

  
  

PERSISTENCE AND DEGRADABILITY 

No data available 
 ECOTOXICITY

 No data available 
  

 
 SECTION 13. WASTE DISPOSAL METHODS 

  
  

DO NOT DUMP DOWN THE SINK, INTO ANY SEWERS, ON THE GROUND OR INTO ANY BODY OF WATER. All wastes containing material should be properly labeled.
Dispose of waste according to prescribe federal, state and local guidelines, e.g. appropriately permitted chemical waste incinerator. 
  

 
 SECTION 14. TRANSPORTATION INFORMATION

  
  

DOT (US) 
 Not dangerous goods

 IMDG 
 Not dangerous
goods 
 IATA 
 Not
dangerous goods 
  
  

SECTION 15. LABELING/REGULATORY INFORMATION 
  

 
 Containers of this material should have
affixed the following label (in addition to the identity label) and hazard, handling, storage and other conditions: 

 CAUTION! Chemical intended for R&D purposes only to be handled by trained personnel. The
toxicity of this chemical and potential target organ toxicity is not fully known. Avoid skin contact, eye contact, inhalation, and ingestion. 

REGULATORY NUMBER LIST 
  

			
	 FEMA #:
	  	 3839

	 FL#:
	  	 01.041

	 CoE#:
	  	 10999

	 EINECS #:
	  	 242-582-0

	 ENCS #:
	  	 2-2360

	 ECL Serial #:
	  	 KE-11524

 US RISK CLASSIFICATION
LABEL: 
 Not applicable 

EU RISK AND SAFETY PHRASES (according to Directive 67/548/EEC). 

Handle in accordance with good industrial hygiene and safety practice. 

 

			
	 Symbol:
	  	
	 S24/25:
	  	 Avoid contact with skin and eyes.

	 S36:
	  	 Wear suitable protective clothing.

EUROPEAN COMMUNITY LEGISLATION 

Official Journal of the European Communities, No. L 49 (20 Feb 2002). 

This substance is listed in the Register of Flavouring Substances pursuant to Article 3(1) of Regulation EC No. 2232/96 (28 Oct 1996) that lays
down a procedure for flavouring substances used or intended for use in or on foodstuffs. 
 Listed Name(s): ß-Farnesene. 

FL #: 01.041. 
 FEMA #.: 3839.

 CoE #: 10999. 
 Chemical
Group: 31. 
 Comments: Name, CAS, EINECS, CoE, or FEMA number might contain inconsistencies. 

Official Journal of the European Communities, No L 84 (27 Mar 1999). 

This substance is listed in the Register of Flavouring Substances pursuant to Article 3(1) of Regulation EC No. 2232/96 (28 Oct 1996) that lays
down a procedure for flavouring substances used or intended for use in or on foodstuffs. Adopted February 23, 1999. 
 Listed Name(s):
ß-Farnesene 
 CoE No. 10999 

Official Journal of the European Communities, No L 132 (1 Jun 1996). 

Publication of Commission Decision 96/335/EC of 8 May 1996 establishing an inventory and a common nomenclature of ingredients employed in
cosmetic products in accordance with Article 6(1) of the cosmetic products Directive 76/768/EEC. This substance is listed in Section II. 

INCI name: (E)-7,11-Dimethyl-3-methylenedodeca-1,6,10-triene. 

SARA hazard Category Sections 311 and 312 

None applicable 
 TSCA

 Listed on July 2008 Inventory 

 CERCLA 

Not listed 
 CaIifornia Prop 65

 Not listed 

EINECS: 
 Annex to Official
Journal of the European Communities, 15 June 1990 
 ENCS: 

Japanese Gazette. Contained within class: Low Molecular Chain-like Organic Compounds. 

OTHERS: 
 Canadian Domestic
Substances List (DSL): Yes; Supplement to Canada Gazette, January 26 1991 
 Canadian Non-Domestic Substances List (NDSL): No

 Existing Chemicals List (Korea): Yes; January 1997 

Australian Inventory of Chem. Substances: Yes; June 1996 

Phillippine Inventory of Chem. Substances (PICCS): Yes; 2000 

Swiss Poison List 1 (Substances): No 
  

 
 SECTION 16. OTHER INFORMATION

  
  

No additional information. 

Abbreviations: 
 ACGIH: American
Conference of Governmental Industrial Hygienists 
 AICS: Australian Inventory of Chemical Substances 

ASIA-PAC: Chemical substances that are on one or more of the chemical inventories from the following countries in the Asia-Pacific region:
Australia, China, Japan, Korea, Philippines and Taiwan 
 CERCLA: Comprehensive Environmental Response Compensation and Liability Act
(Superfund) 
 CoE: Council of Europe 

DOT: Department of Transportation 

DSL: Domestic Substances List (Canada) 

ECL: Existing Chemicals List (Korea) 

EINECS: European Inventory of Existing Chemical Substances 

ENCS: Existing and New Chemical Substances (Japan) 

EU: European Union 
 FEMA: Flavour
and Extract Manufacturers Association 
 FL: European Flavouring Number 

IARC: International Agency for Research on Cancer 

IATA: International Air Transport Association 

MSHA: Mine Safety and Health Administration 

NDSL: Non-domestic Substances List (Canada) 

NTP: National Toxicology Program 

OSHA: Occupational Safety and Health Administration 

PICCS: Philippine Inventory of Chemicals and Chemical Substances 

SARA: Superfund Amendment and Reauthorization Act of 1986 (SARA Title III) 

TSCA: Toxic Substances Control Act 

************************************************************************************************************************** 

********* 

 This information is based on data available to us and is believed to be correct. Since the information
may be applied under conditions beyond our control and with which we may be unfamiliar, we do not assume any responsibility for the results of its use and all persons receiving it must make their own determination of the effects, properties and
protections, which pertain to their particular conditions. 
 No representation, warranty, or guarantee, express or implied (including a
warranty of fitness or merchantability for a particular purpose), is made with respect to the materials, the accuracy of this information, the results to be obtained from the use thereof, or the hazards connected with the use of the material.
Caution should be used in the handling and use of the material because it may be hazardous.Free Lease Agreement

 Exhibit 10.50 

CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS 

DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR 

CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE, HAVE BEEN MARKED 

WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE 

CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH 

THE SECURITIES AND EXCHANGE COMMISSION. 

FREE LEASE AGREEMENT (COMODATO) 

By means of this private legal instrument, on the one side, 

AMYRIS BRASIL S.A., a corporation organized and existing under Brazilian law, with its head office located in the City of
Campinas, State of São Paulo, Federal Republic of Brazil, at Rua James Clerk Maxwell, 315, enrolled with the General Registry of Corporate Taxpayers of the Brazilian Ministry of Finance (“CNPJ/MF”) under
No. 09.379.224/0001-20, herein represented by its undersigned legal representatives (“AMYRIS”), 
 and, on
the other side, 
 BIOMIN DO BRASIL NUTRIÇÃO ANIMAL LTDA., a corporation organized and existing under
Brazilian law, with its head office located in the City of Piracicaba, State of São Paulo, at Estrada Professor Messias Jose Baptista, 2700, enrolled with the CNPJ/MF under No. 07.738.662/0001-02, herein represented by its undersigned
legal representatives (“BDB”), 
 (AMYRIS and BDB are individually identified as “Party” and
jointly as “Parties”). 
 RECITALS 

WHEREAS: 
  

	(A)	 the Parties executed a Joint Manufacturing Agreement, dated as of June 24, 2010, whereby BDB agreed to manufacture, in its facility located
in Piracicaba, certain products specifically required by AMYRIS according to the terms and conditions set forth in such agreement (“Joint Manufacturing Agreement” and “Product”, respectively);

  

	(B)	 under the Joint Manufacturing Agreement, AMYRIS agreed to entrust BDB with the manufacture of the Products, providing BDB with the necessary
information and equipment, as well as paying BDB a consideration; 

  

	(C)	 under the Joint Manufacturing Agreement, AMYRIS agreed to assign to BDB the certain equipments, under a free lease agreement
(comodato) for the effective period of the Joint Manufacturing Agreement; and 

  

	(D)	 the Parties are interested in setting forth the conditions applicable to the above mentioned free lease (comodato) agreement.

 The Parties hereby resolve to execute this Free Lease Agreement (Comodato) (the
“Agreement”), which shall be governed by the following clauses and conditions: 
  

 1 

 CLAUSE ONE – SCOPE 

 

	1.1.	 By this Agreement and on the best terms of the law, AMYRIS grants on temporary basis to BDB the use and possession of certain equipments,
free of charge, and retaining title to such equipment to be used exclusively for the manufacturing of the Product (the “Free Leased Equipment”). A detailed description of the Free Leased Equipment and estimation of its cost of
acquisition is attached hereto as Annex A. 

  

	1.2.	 This Free Lease agreement shall be read as an ancillary agreement to the Joint Manufactured Agreement and at all times constructed in the
context of such an agreement. In case of conflict between any provisions of the Free Lease Agreement and the Joint Manufacturing Agreement the Joint Manufacturing Agreement prevails. 

CLAUSE TWO – DESTINATION 

2.1.      During the term of the Agreement, the Free Leased Equipment shall be exclusively used for
the specified activities of BDB described on the Joint Manufacturing Agreement. 
 CLAUSE THREE – TERM 

3.1.      This Agreement shall be effective as from the date of execution hereof until the date of
expiration or termination of the Joint Manufacturing Agreement, and shall be automatically terminated when the Joint Manufacturing Agreement is terminated or expired in accordance with the provisions thereof. 

CLAUSE FOUR – PURCHASE OPTION 

4.1.      Following a period of two (2) years as of the Effective Date of the Joint
Manufacturing Agreement, BDB shall have the option to purchase the Equipment for a price equal to total Project Capex less taxes less depreciation accrued in accordance with applicable law, as defined in the Joint Manufacturing Agreement.

 4.2       If BDB does not exercise the option referred to in Section 4.1 after a
period of two (2) years as of the Effective Date, in the third anniversary of this Agreement, BDB shall have a final option to purchase the Equipment for the price defined in Section 4.1. 

4.3.      The Parties hereby agree that the Purchase Option provided for in this section 4 and in the Joint
Manufacturing Agreement shall comprehend the whole of the Equipment and, hence, the total Project Capex. [*]. 

4.4.      Unless in the event BDB decides to not exercise the purchase option or the Joint Manufacturing
Agreement is terminated in breach of BDB’s obligations thereunder, AMYRIS shall transfer definitive ownership of the Free Leased Equipment to BDB, within eight (8) weeks after expiration or termination of the Toll Manufacturing Agreement.
BDB shall permit Amyris to remove the equipment and any materials of the Unit that can be removed without 
  

 

* Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 2 

 causing any material harm to the site. 

4.5.      For the purposes of the Joint Manufacturing Agreement and in compliance with the applicable law,
depreciation will begin to accrue once BDB’s plant is in operation and hence manufacturing of the Product has actually started. 

4.6       Any title of AMYRIS to the Free Leased Equipment shall cease upon final payment of all
amounts due according to Clause 4.1 above and BDB shall gain unfettered ownership of the Free Leased Equipment following receipt by AMYRIS of all such amounts. 

4.8       In the event that BDB, for any reason, does not pay the full price of the Free Leased
Equipment pursuant to this Clause, within 15 days of the exercise of the purchase option, BDB shall permit AMYRIS to remove the Free Leased Equipment and any related materials, as provided for in Clause 4.2, without causing any material harm to the
Plant. 
 CLAUSE FIVE – DELIVERY AND INSTALLATION 

5.1.      BDB expressly acknowledges that, from date the delivery of Free Leased Equipment at
BDB’s plant located in the City of Piracicaba, São Paulo, Brazil, BDB will have the possession of the Free Leased Equipment, taking all responsibilities to preserve the Free Lease Equipment. 

5.2.      BDB undertakes to keep for the term of this Free Lease Equipment Agreement the Free Leased
Equipment installed at its plant located in the City of Piracicaba, São Paulo, Brazil, pursuant to the installation instructions provided by AMYRIS. BDB shall not take the Free Leased Equipment out of its plant without the prior written
consent of AMYRIS. 
 5.3.      AMYRIS shall be entitled, but not required, to appoint the
person or persons who it may deem appropriate to inspect if BDB is adequately operating the Free Leased Equipment, but under no circumstances AMYRIS shall be held liable for the installation or proper operation of the Free Leased Equipment.

 CLAUSE SIX – OWNERSHIP 

6.1       The Free Leased Equipment shall be kept as exclusive property of AMYRIS, and it shall not
become a part of the real property of BDB. BDB undertakes to not create any lien or encumbrance on the Free Leased Equipment. In addition, BDB shall not remove the plate attached to the Free Leased Equipment indicating AMYRIS’s property.

 6.2       BDB may not lease, deliver or transfer the Free Leased Equipment to any other
person. BDB shall not create or allow the creation of any privilege or preemptive right, injunction, or encumbrance of any type on the Free Leased Equipment. In case any event occurs that may threaten or adversely affect AMYRIS’s ownership of
the Free Leased Equipment or create any encumbrance on the Free Leased Equipment, BDB shall promptly give notice to AMYRIS, and defend AMYRIS’s ownership, at its own account, as diligently as possible, unless AMYRIS, at its own discretion,
determines to defend such ownership at its own account. In such case, the legal fees and further expenses shall be borne by BDB 

6.3       BDB shall notify and warn all those threatening to damage or jeopardize 

 

 3 

 the ownership of the Free Leased Equipment that belongs to AMYRIS for all purposes. BDB
shall be liable for and accepts to indemnify, exempt and release AMYRIS from and against any liability, loss, expense or any other damage arising out of such threat, damage or loss. 

CLAUSE SEVEN – USE, MAINTENANCE, IMPROVEMENTS, INSPECTION AND DAMAGES 

7.1       The Free Leased Equipment shall exclusively be used for the purpose agreed to in the Joint
Manufacturing Agreement. 
 7.2.      BDB shall supply all power, water, heat and other
services that may be necessary to operate the Free Leased Equipment. 
 7.3.      BDB
accepts to be fully responsible for the operation of the Free Leased Equipment,. 

7.4.      BDB agrees to care for the good conservation and maintenance of the Free Leased Equipment
as if it were BDB’s own asset. 
 7.5       BDB shall not make modifications,
replacements or changes in the Free Leased Equipment, without the prior written consent by AMYRIS, and BDB shall not replace nor disassemble the Free Leased Equipment in order to use its parts in any other equipment. 

7.6.      AMYRIS reserves itself the right to make replacements or changes in the Free Leased
Equipment with the purpose of improving its yield and usefulness. The dates and time necessary for such work shall be agreed between the parties. 

7.7.      BDB agrees to allow AMYRIS to inspect the Free Leased Equipment whenever AMYRIS desires,
within working hours and as previously scheduled in advance by the Parties. 

7.8.      BDB agrees to immediately repair, at its sole and exclusive cost, any damages to which it
may give cause to the Free Leased Equipment. If such repair is not possible, BDB shall indemnify AMYRIS for the resulting losses, within no longer than [ninety (90) days] as from the occurrence such damage. 

CLAUSE EIGHT – INDEMNIFICATION 

8.1.      AMYRIS shall not be held liable for any damage, loss, injury or death incurred by BDB or
by any other person or asset (including, but not limited to, products processed by use of the Free Leased Equipment), resulting from or arising out of, or in any manner relating to the operation and maintenance by BDB, lack of use, replacement or
return of the Free Leased Equipment, or for the use of any material, device or processing method relating thereto. 

8.2.      BDB undertakes to indemnify, exempt and release AMYRIS from and against any obligation, damage,
loss, cost or expense of any nature whatsoever owed or borne by AMYRIS due to the aforementioned loss, damage, or injury, or death resulting from the use of the Free Leased Equipment by BDB. 

 

 4 

 8.3       Upon being aware of any such mentioned event,
BDB shall inform AMYRIS on any demand or judicial action arising out of the use of the Free Leased Equipment. AMYRIS shall undertake the defense of any judicial claim or action through its own attorneys. BDB shall pay all costs in connection with
the mentioned defense 
 CLAUSE NINE – TAXES AND EXPENSES 

9.1.       AMYRIS shall bear all expenses relating to shipping, including packaging, domestic
and sea freight, transportation insurance, import and export agents’ fees, etc., and it shall further bear all customs expenses, including import rights, import expenses and any other taxes and expenses related to the Free Leased Equipment

 CLAUSE TEN – GENERAL PROVISIONS 

10.1.    Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in
the Joint Manufacturing Agreement, as the context requires 
 10.2    The Parties shall not
assign or transfer (in whole or in part) its rights or obligations under this Free Lease Agreement without the prior written consent of the other Party. 

10.3.    This Agreement binds the Parties and/or successors on any degrees whatsoever 

10.4.    This Agreement may only be amended or modified by means of prior agreement between the Parties and
the signing of a specific amendment signed by both. 
 10.5.    Any omission or tolerance by the
Parties in requiring the correct, full and punctual compliance with the specific or generic terms and conditions contained in this Agreement, or in exercising any prerogative hereunder, shall not constitute any kind of waiver, desistance or
novation, and nor shall it affect the right of the Parties to exercise them at any time. 

10.6.    In the event any provision of this Agreement should be considered invalid, illegal or unenforceable
for any reason, the validity, legality and enforceability of the remaining provisions contained in this Agreement shall not in any manner whatsoever be affected or prejudiced thereby and shall remain in full force and effect. The Parties shall
negotiate in good faith to replace any provisions considered invalid, illegal or unenforceable with valid, legal and enforceable provisions, the effects of which shall approximate as closely as possible the legal and economic effects intended by the
provisions considered invalid, illegal or unenforceable. 
 10.7     None of the Parties shall be
liable to the other Party for the breach to this Agreement, if such breach is caused by force majeure, including, but not limited to, fire, explosion, labor conflict (including strike and lockout), rebellion, uprising, failure or delay in obtaining
authorizations or material, lack of supply sources, governmental provisions, interruptions in public means of transportation, war, accidents, acts of God or force majeure or public enemy, or other similar or different factors, beyond the control of
both Parties. 
  

 5 

 10.8    This Agreement does not create or intend to create any kind of
company, association, joint venture, cooperative, partnership, consortium, or agency, and neither does it attribute or aim to create any kind of relationship involving principal and agent, commercial representation, business management or other kind
of similar legal arrangement between the Parties, except for those expressly provided in this Agreement and in the Joint Manufacturing Agreement. 

10.9    Each Party is responsible for covering its own costs and other expenses incurred or to be incurred in
relation to the signing, execution and performance of this Agreement. 
 10.10    Should, after the
signature of this Agreement, any taxes be created, or any tax rates, taxable base or manners for calculating any tax existing at the signing date below and involving taxable events related in any manner to this Agreement be altered, either via a
law, a decree, a ruling or an administrative rule, or any special tax benefit available to the Parties related to this Agreement granted by any federal, state of municipal taxing authorities be extinguished, the Parties shall negotiate, in good
faith, to amend this Agreement in order to restore its economic and financial balance. 
 CLAUSE ELEVEN – CONFIDENTIALITY

 11.1    BDB agrees that all materials and information made available to him by AMYRIS or by his
order, before or during the term of this Agreement, including any manual, shall be considered trade secrets of AMYRIS for the purposes of this Agreement, and shall be held as confidential and used by BDB solely for the purposes permitted herein. BDB
agrees not to release the trade secrets to the public or other persons besides its employees, and even to its employees only to the necessary extent as to the accomplishment of this Agreement. BDB also agrees not to permit that anyone copy or
exhibit any confidential information received from AMYRIS. The communication, delivery or release of the trade secrets or other confidential information by AMYRIS to BDB, its employees or representatives, shall not be construed or interpreted as a
license or assignment of intellectual property rights, but only as authorization for BDB to use such information for the accomplishment of its obligations under this Agreement. 

CLAUSE TWELVE – COMMUNICATIONS 

12.1.    All notices, communications, requests, authorizations and consents that have to be transmitted
or given by the Parties under this Agreement shall only be valid and effective if provided in writing through correspondence (under protocol or sent against notice of receipt) or fax (with proof of transmission) addressed in the following
manner (or in such other manner as may be notified subsequently by one Party to the other): 

(a)        AMYRIS: 

 

			
	 Address:
	  	Rua James Clerk Maxwell, 315, Campinas-SP
	 Phone:
	  	+55 19 3783-9450
	 Fax:
	  	+55 19 3783-9450
	 At.:
	  	Roel Win Collier

(b)        BDB: 

 

 6 

			
	 Address:
	  	Estrada Professor Messias Batista, 2007, Piracicaba-SP
	 Phone:
	  	+55 19 3415-9900
	 Fax:
	  	+55 19 3415-9900
	 At.:
	  	Edilberto Ferreira

12.2.    BDB shall give immediate written notice to AMYRIS as soon as BDB becomes aware of any act, fact or
event that may or might turn out to affect in any manner the possession of the Free Leased Equipment. 
 CLAUSE THIRTEEN
– APPLICABLE LAW AND DISPUTE RESOLUTION 
 13.1.    This Agreement shall be governed by the
laws of Brazil. 
 13.2.    The Parties will use best efforts to resolve any difference of opinion
and dispute in friendly negotiations. 
 13.3.    If friendly negotiations pursuant to Clause 13.2.
do not result in an agreement within ninety (90) days from the first communication sent by one Party to the other on the relevant matter, all disputes arising out of or in connection with this Agreement shall be exclusively and finally settled
by arbitration as provided for in Clause 17 of the Joint Manufacturing Agreement. 
 In witness whereof, the Parties have caused
this Agreement to be executed in two (2) counterparts with the same form and contents, before the two (2) undersigned witnesses. 

São Paulo, June 24, 2010 

Intentionally left blank — signature pages following 

 

 7 

 Signature Page 1/3 of the Free Lease Agreement (Comodato), entered into as of June 24,
2010, between Amyris 
 Brasil S.A. and Biomin do Brasil Nutrição Animal Ltda. 

AMYRIS BRASIL S.A. 
  

			
	 /s/ Roel Win Collier
	 	 /s/ Felipe Moreira Caram

	 Name: Roel Win Collier

Title: General Manager
	 	 Name: Felipe Moreira Caram

Title: Financial Officer

  

 8 

 Signature Page 2/3 of the Free Lease Agreement (Comodato), entered into as of June 24,
2010, between Amyris Brasil S.A. and Biomin do Brasil Nutrição Animal Ltda. 
 BIOMIN DO BRASIL
NUTRIÇÃO ANIMAL LTDA. 
  

			
	 /s/ Herbert Danner
	 	 /s/ Edilberto Ferreira

	 Name: Herbert Danner

Title: General Manager
	 	 Name: Edilberto Ferreira

Title: Financial Officer

  

 9 

 Signature Page 3/3 of the Free Lease Agreement (Comodato), entered into as of June 24,
2010, between Amyris Brasil S.A. and Biomin do Brasil Nutrição Animal Ltda. 
 Witnesses: 

 

			
	  
	 	  

	 Name:

ID (RG) No.:
 Tax
Reg. (CPF/MF) No.:
	 	 Name:

ID (RG) No.:
 Tax
Reg. (CPF/MF) No.:

  

 10 

 ANNEX A 

Description of the Free Leased Equipment 
  

			
	  	  	Equipment
	 First 200 m3 fermentor
	  	 •     Production fermentor

•     Compressed air system

•     Media sterilization system

•     Inactivation system

•     Seed fermentor

•     CIP system

		
	 Second 200m3 fermentor
	  	 •     Production fermentor

•     Compressed air system

•     Cooling tower

 

 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00175-of-00352.parquet"}]]